New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - tranexamic acid 500mg - film coated tablet - 500 mg - active: tranexamic acid 500mg excipient: basic butylated methacrylate copolymer colloidal silicon dioxide croscarmellose sodium isopropyl alcohol macrogol 8000 magnesium stearate   microcrystalline cellulose povidone purified talc   purified water titanium dioxide vanillin - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. local fibrinolysis may occur in the following conditions: -prostatectomy and bladder surgery -menorrhagia -epistaxis -conisation of the cervix - management of dental extraction in patients with coagulopathies - ulcerative colitis - haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma) -gastrointestinal haemorrhage general fibrinolysis as in prostatic and pancreatic cancer; after thoracic and other major surgery: - in obstetrical complications such as abruptio placentae and post-partum haemorrhage - in leukaemia and liver diseases and in connection with thrombolytic therapy with streptokinase hereditary angioneurotic oedema. for the reduction of peri– and post-operative blood loss and the need for blood transfusion in adult patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. for the reduction of peri- and post-operative blood loss and the need for blood transfusion in paediatric patients undergoing cardiac surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - ursodeoxycholic acid 250mg;  ;   - capsule - 250 mg - active: ursodeoxycholic acid 250mg     excipient: capsugel white op colloidal silicon dioxide magnesium stearate maize starch pregelatinised maize starch - ursosan is indicated in the treatment of chronic cholestatic liver diseases, including primary biliary cirrhosis (pbc) and primary sclerosing cholangitis (psc). in primary biliary cirrhosis ursodeoxycholic acid improves liver enzymes and igm and prevents worsening of liver histology in patients with less advanced forms of the disease, i.e. serum bilirubin less that 2 mg/dl and histologic changes in liver confined to the portal regions. prevention of complications of chronic liver disease has not been established.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - noradrenaline acid tartrate 2 mg/ml equivalent to 1 mg/ml noradrenaline base;   - concentrate for injection - 1 mg/ml - active: noradrenaline acid tartrate 2 mg/ml equivalent to 1 mg/ml noradrenaline base   excipient: nitrogen sodium chloride water for injection - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusions and drug reactions). as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; maize starch; magnesium stearate - 1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes. b) due to dual av nodal pathways in patients with debilitating symptoms. c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms.,although flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide bnm tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; croscarmellose sodium; maize starch - 1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes. b) due to dual av nodal pathways in patients with debilitating symptoms. c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms.,although flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide bnm tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - oxycodone hydrochloride, quantity: 5 mg - capsule, hard - excipient ingredients: gelatin; microcrystalline cellulose; iron oxide red; sodium laureth sulfate; titanium dioxide; indigo carmine; iron oxide yellow; magnesium stearate - oxycodone bnm is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - oxycodone hydrochloride, quantity: 20 mg - capsule, hard - excipient ingredients: iron oxide red; magnesium stearate; microcrystalline cellulose; titanium dioxide; indigo carmine; gelatin; sodium laureth sulfate; iron oxide yellow - oxycodone bnm is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - oxycodone hydrochloride, quantity: 10 mg - capsule, hard - excipient ingredients: gelatin; iron oxide red; titanium dioxide; microcrystalline cellulose; indigo carmine; magnesium stearate; iron oxide yellow; sodium laureth sulfate - oxycodone bnm is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ferrous fumarate, quantity: 304.2 mg; ascorbic acid, quantity: 20 mg - capsule, hard - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; stearic acid; polyacrylate dispersion (30 per cent); purified water; gelatin; sodium laureth sulfate - for the prevention and treatment of iron deficiency anaemia, iron and vitamin c supplementation, which may help relieve fatigue, where dietary intake for both nutrients is inadequate.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - noradrenaline acid tartrate monohydrate 0.4 mg/ml equivalent to noradrenaline 0.2mg/ml;   - solution for infusion - 10 mg/50ml - active: noradrenaline acid tartrate monohydrate 0.4 mg/ml equivalent to noradrenaline 0.2mg/ml   excipient: hydrochloric acid sodium chloride water for injection - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions). as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.